Achillion Pharmaceuticals Inc (NASDAQ:ACHN)

10.06
Delayed Data
As of Apr 24
 +0.06 / +0.60%
Today’s Change
2.45
Today|||52-Week Range
16.87
-17.88%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative treatments for infectious diseases. The company is currently engaged in the development of antivirals for the treatment of chronic hepatitis C infection and resistant bacterial infections. Its products include ACH-3102, ACH-2684, Sovaprevir and ACH-3422. Achillion Pharmaceuticals was founded on August 17, 1998 and is headquartered in New Haven, CT.

Contact Information

Achillion Pharmaceuticals, Inc.
300 George Street
New Haven Connecticut 06511
P:(203) 624-7000
Investor Relations:
(203) 752-5510

Employees

Shareholders

Mutual fund holders44.44%
Other institutional33.56%
Individual stakeholders30.86%

Top Executives

Milind S. DeshpandePresident, Chief Executive Officer & Director
Mary Kay FentonCFO, Secretary, EVP & Investor Relations Contact
David ApelianChief Medical Officer & Executive Vice President
Joseph TruittChief Commercial Officer & Executive VP
Glenn SchulmanHead-Investor Relations

To view my watchlist

Not a member yet?

Sign up now for a free account